HRP20160553T1 - Agonisti receptora neurotrofina i njihova uporaba kao lijekova - Google Patents
Agonisti receptora neurotrofina i njihova uporaba kao lijekova Download PDFInfo
- Publication number
- HRP20160553T1 HRP20160553T1 HRP20160553TT HRP20160553T HRP20160553T1 HR P20160553 T1 HRP20160553 T1 HR P20160553T1 HR P20160553T T HRP20160553T T HR P20160553TT HR P20160553 T HRP20160553 T HR P20160553T HR P20160553 T1 HRP20160553 T1 HR P20160553T1
- Authority
- HR
- Croatia
- Prior art keywords
- substance
- disease
- receptor
- pharmaceutically acceptable
- medication
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 17
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 title claims 3
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 title claims 3
- 239000000556 agonist Substances 0.000 title 1
- 239000000126 substance Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 12
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 230000000638 stimulation Effects 0.000 claims 6
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003900 neurotrophic factor Substances 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 230000000324 neuroprotective effect Effects 0.000 claims 4
- 102000015534 trkB Receptor Human genes 0.000 claims 4
- 108010064880 trkB Receptor Proteins 0.000 claims 4
- -1 2-oxo-pyrrolidin-1-ylmethyl Chemical group 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229940053128 nerve growth factor Drugs 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010065681 HIV peripheral neuropathy Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000002037 lung adenoma Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- 230000003018 neuroregenerative effect Effects 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 102000015533 trkA Receptor Human genes 0.000 claims 1
- 108010064884 trkA Receptor Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (18)
1. Tvar koja ima formulu II:
[image]
ili njena farmaceutski prihvatljiva sol, pri čemu:
R1 je fenil supstituiran halogenom ili trifluorometilom i nadalje opcionalno supstituiran s jednim ili dva supstituenta odabranih iz grupe koja se sastoji od halogena, C1-6 alkila, (C1-6)alkoksi i halo (C1-6)alkila; i
R2 je 2-okso-pirolidin-1-ilmetil ili sulfamoilfenil.
2. Tvar iz patentnog zahtjeva 1, pri čemu je R1 fluorofenil, a R2 je definiran u patentnom zahtjevu 1, pri čemu je poželjno R1 2-fluorofenil.
3. Tvar iz patentnog zahtjeva 1 ili patentnog zahtejva 2, pri čemu je R2 4-sulfamoilfenil.
4. Tvar iz patentnog zahtjeva 1, ima formulu III:
[image]
ili formulu IV:
[image]
ili njena farmaceutski prihvatljiva sol.
5. Tvar iz bilo kojeg od patentnih zahtjeva 1-4, ili farmaceutski prihvatljiva sol, za uporabu kao lijek.
6. Farmaceutski sastav, sadrži terapijski učinkovitu količinu barem jedne tvari iz bilo kojeg od patentnih zahtjeva 1-5, i farmaceutski prihvatljivi nosač.
7. Tvar iz patentnog zahtjeva 5 ili farmaceutski sastav iz patentnog zahtjeva 6 za uporabu kao lijek koristan u prevenciji ili liječenju smrti ili oštećenja živčanih stanica; obnavljanju živčanih stanica ili u prevenciji ili liječenju neurološke ili psihijatrijske bolesti.
8. Tvar za uporabu iz patentnog zahtjeva 5, pri čemu je medikament neuroprotektivni lijek ili neuropobuđujući lijek; ili neuroregenerativni lijek ili imunomodulator.
9. Tvar za uporabu iz patentnog zahtjeva 5 ili farmaceutski sastav iz patentnog zahtjeva 6, pri čemu je medikament ili farmaceutski sastav koristan u prevenciji ili liječenju bolesti odabrane između: neuroloških bolesti, poželjno neurodegenerativnih poremećaja, kao što su amiotrofna lateralna skleroza (ALS), Parkinsonova bolest, Alzheimerova bolest, Friedrichova ataksija, Huntingtonova bolest, demencija s Lewyjevim tjelešcima, spinalna muskularna atrofija; upale živca, kao što je multipla skleroza ili optički neuromijelitis, veliki depresivni poremećaj; shizofrenije; glaukoma; periferne neuropatija, kao što je dijabetička ili AIDS neuropatija; i raka, kao što je glioblastom, astrocitom, meduloblastom, neurinom, neuroblastom, meningiom, rak kolona, rak gušterače, rak dojke, rak prostate, leukemija, akutna limfocitna leukemija, osteosarkom, hepatocelularni karcinom, karcinom jajnika, adenom pluća i karcinom jednjaka.
10. Tvar za uporabu iz patentnog zahtjeva 5 ili farmaceutski sastav iz patentnog zahtjeva 6, pri čemu medikament ili farmaceutski sastav ima kombinaciju neuroprotektivnog i imunomodulatornog učinka.
11. Uporaba tvari iz bilo kojeg od patentnih zahtjeva 1-5 kao aktivnog sastojka u proizvodnji medikamenta za prevenciju ili liječenje smrti ili oštećenja živčanih stanica; ili neuroprotektivnog medikamenta; ili medikament za obnavljanje živčanih stanica; ili medikamenta za prevenciju ili liječenje neurološke ili psihijatrijske bolesti ili neuroregenerativnog lijeka; ili imunomodulatora; ili medikamenta koji ima kombinaciju neuroprotektivnog i imunomodulatornog učinka; ili neuropobuđujućeg lijeka.
12. Uporaba tvari iz bilo kojeg od patentnih zahtjeva 1-5 kao aktivnog sastojka u proizvodnji medikamenta za prevenciju ili liječenje bolesti odabrane između: neuroloških bolesti, poželjno neurodegenerativnih poremećaja, kao što su amiotrofna lateralna skleroza (ALS), Parkinsonova bolest, Alzheimerova bolest, Friedrichova ataksija, Huntingtonova bolest, Demencija s Lewyjevim tjelešcima, spinalna muskularna atrofija; upale živca, kao što je multipla skleroza ili optički neuromijelitis, velikih depresivnih poremećaj; shizofrenije; glaukoma; periferne neuropatije, kao što je dijabetička ili AIDS neuropatija; i raka, kao što je glioblastom, astrocitom, meduloblastom, neurinom, neuroblastom, meningiom, rak kolona, rak gušterače, rak dojke, rak prostate, leukemija, akutna limfocitna leukemija, osteosarkom, hepatocelularni karcinom, karcinom jajnika, adenom pluća i karcinom jednjaka.
13. Tvar iz bilo kojeg od patentnih zahtjeva 1-5 ili njena farmaceutski prihvatljiva sol, za uporabu u metodi za stimuliranje aktivnosti živčanog faktora rasta, ili receptora živčanog faktora rasta, ili u metodi za liječenje bolesti koja odgovara na stimulaciju aktivnosti živčanog faktora rasta, ili receptora živčanog faktora rasta, u sisavaca koji pate od nedostatka njegove stimulacije.
14. Tvar za uporabu navedenu u patentnom zahtjevu 13, pri čemu je receptor živčanog faktora rasta TrkA receptor ili p75 receptor.
15. Tvar iz bilo kojeg od patentnih zahtjeva 1-5 ili njena farmaceutski prihvatljiva sol, za uporabu u metodi za stimuliranje aktivnosti neurotrofinskog faktora, ili receptora neurotrofinskog faktora , ili u metodi za liječenje bolesti koja odgovara na stimulaciju aktivnosti neurotrofinskog faktora, ili receptora neurotrofinskog faktora, u sisavaca koji pate od nedostatka njegove stimulacije.
16. Tvar iz bilo kojeg od patentnih zahtjeva 1-5 ili njena farmaceutski prihvatljiva sol, za uporabu u metodi za stimuliranje aktivnosti neurotrofnog faktora moždanog porijekla, ili receptora neurotrofnog faktora moždanog porijekla, ili u metodi za liječenje bolesti koja odgovara na stimulaciju aktivnosti neurotrofnog faktora moždanog porijekla, ili receptora neurotrofnog faktora moždanog porijekla, u sisavaca koji pate od nedostatka njegove stimulacije.
17. Tvar za uporabu u skladu s patentnim zahtjevom 16, pri čemu je receptor neurotrofnog faktora moždanog porijekla TrkB receptor ili p75 receptor.
18. Metoda za pripravu farmaceutskog sastava, obuhvaća umješavanje učinkovite količine tvari iz bilo kojeg od patentnog zahtjeva 1-5, ili njene farmaceutski prihvatljive soli, u farmaceutski prihvatljivi nosač.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37882310P | 2010-08-31 | 2010-08-31 | |
| PCT/IB2011/002562 WO2012028959A1 (en) | 2010-08-31 | 2011-08-31 | Agonists of neurotrophin receptors and their use as medicaments |
| EP11788579.8A EP2611775B8 (en) | 2010-08-31 | 2011-08-31 | Agonists of neurotrophin receptors and their use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160553T1 true HRP20160553T1 (hr) | 2016-09-23 |
Family
ID=45048148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160553TT HRP20160553T1 (hr) | 2010-08-31 | 2016-05-23 | Agonisti receptora neurotrofina i njihova uporaba kao lijekova |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8791076B2 (hr) |
| EP (1) | EP2611775B8 (hr) |
| JP (1) | JP5946454B2 (hr) |
| KR (1) | KR101964954B1 (hr) |
| CN (1) | CN103270022B (hr) |
| AU (1) | AU2011298091B2 (hr) |
| BR (1) | BR112013004662B8 (hr) |
| CA (1) | CA2809774C (hr) |
| DK (1) | DK2611775T3 (hr) |
| ES (1) | ES2575684T3 (hr) |
| HR (1) | HRP20160553T1 (hr) |
| HU (1) | HUE029393T2 (hr) |
| IL (1) | IL224972A (hr) |
| MX (1) | MX340233B (hr) |
| PL (1) | PL2611775T3 (hr) |
| PT (1) | PT2611775E (hr) |
| RU (1) | RU2606622C2 (hr) |
| SI (1) | SI2611775T1 (hr) |
| WO (1) | WO2012028959A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289886A1 (en) * | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
| RU2606622C2 (ru) | 2010-08-31 | 2017-01-10 | Бионуре Фарма, С.Л. | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств |
| WO2014100433A1 (en) * | 2012-12-19 | 2014-06-26 | Brown University | Methods for treatment of microcephaly associated autism disorders |
| EP2950095B1 (en) * | 2014-05-28 | 2018-08-29 | Technische Universität Dresden | Cell-based assay and screening methods for modulators of p75NTR signaling |
| WO2018039641A1 (en) * | 2016-08-25 | 2018-03-01 | Pharmatrophix, Inc. | Methods and compounds for treating alcohol use disorders and associated diseases |
| KR101821118B1 (ko) | 2016-09-06 | 2018-01-23 | 가톨릭대학교 산학협력단 | 감보그 산(gambogic acid)을 포함한 알러지성 질환 예방 또는 치료용 조성물 |
| CN107802823A (zh) * | 2017-10-27 | 2018-03-16 | 胡军 | Sh2b衔接蛋白1在治疗帕金森病中的功能应用 |
| CA3105879A1 (en) * | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| KR20210099622A (ko) | 2018-12-05 | 2021-08-12 | 가부시키가이샤 스코히아 파마 | 거대고리 화합물 및 그의 용도 |
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU189214B (en) | 1983-01-20 | 1986-06-30 | Alkaloida Vegyeszeti Gyar,Hu | Process for preparing pyrroline and pyrrolidine carboxamide derivatives |
| US6271205B1 (en) | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
| US5747458A (en) | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
| US6391871B1 (en) | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
| DE19751062A1 (de) | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
| US6124361A (en) | 1997-12-31 | 2000-09-26 | Pfizer Inc | Bicyclo[3.1.0]hexanes and related compounds |
| EP1226127B1 (en) | 2000-05-04 | 2009-07-01 | Basf Se | Substituted phenyl sulfamoyl carboxamides |
| ES2169690B1 (es) | 2000-10-06 | 2004-03-16 | Diverdrugs Sl | Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen. |
| ES2169691B1 (es) * | 2000-10-11 | 2004-03-16 | Diverdrugs Sl | Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen. |
| US20050009847A1 (en) | 2002-11-20 | 2005-01-13 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| DE10303229B4 (de) | 2003-01-28 | 2007-07-26 | Keyneurotek Ag | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
| US20110052603A1 (en) | 2006-10-06 | 2011-03-03 | The Walter And Eliza Hall Institute Of Medical Research | method of treatment and agents useful for same |
| EP1994944A1 (en) * | 2007-05-21 | 2008-11-26 | Laboratorios SALVAT, S.A. | Polymer conjugate compounds for the inhibition of apoptosis |
| EP2354225B1 (en) | 2008-09-24 | 2015-04-22 | Ribomic Inc. | Aptamer for ngf and use thereof |
| RU2410392C2 (ru) * | 2009-02-16 | 2011-01-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН | Дипептидные миметики нейротрофинов ngf и bdnf |
| EP2289886A1 (en) | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
| EP2289882A1 (en) | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments |
| RU2606622C2 (ru) | 2010-08-31 | 2017-01-10 | Бионуре Фарма, С.Л. | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств |
-
2011
- 2011-08-31 RU RU2013113634A patent/RU2606622C2/ru active
- 2011-08-31 BR BR112013004662A patent/BR112013004662B8/pt active IP Right Grant
- 2011-08-31 SI SI201130839A patent/SI2611775T1/sl unknown
- 2011-08-31 WO PCT/IB2011/002562 patent/WO2012028959A1/en active Application Filing
- 2011-08-31 ES ES11788579.8T patent/ES2575684T3/es active Active
- 2011-08-31 PT PT117885798T patent/PT2611775E/pt unknown
- 2011-08-31 AU AU2011298091A patent/AU2011298091B2/en active Active
- 2011-08-31 PL PL11788579.8T patent/PL2611775T3/pl unknown
- 2011-08-31 CA CA2809774A patent/CA2809774C/en active Active
- 2011-08-31 DK DK11788579.8T patent/DK2611775T3/en active
- 2011-08-31 JP JP2013526566A patent/JP5946454B2/ja active Active
- 2011-08-31 CN CN201180049622.8A patent/CN103270022B/zh active Active
- 2011-08-31 HU HUE11788579A patent/HUE029393T2/en unknown
- 2011-08-31 US US13/223,166 patent/US8791076B2/en active Active
- 2011-08-31 MX MX2013002329A patent/MX340233B/es active IP Right Grant
- 2011-08-31 KR KR1020137008259A patent/KR101964954B1/ko active IP Right Grant
- 2011-08-31 EP EP11788579.8A patent/EP2611775B8/en active Active
-
2013
- 2013-02-28 IL IL224972A patent/IL224972A/en active IP Right Grant
-
2014
- 2014-06-11 US US14/301,981 patent/US9453047B2/en active Active
-
2016
- 2016-05-23 HR HRP20160553TT patent/HRP20160553T1/hr unknown
- 2016-09-09 US US15/261,410 patent/US10106577B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160553T1 (hr) | Agonisti receptora neurotrofina i njihova uporaba kao lijekova | |
| JP2013536833A5 (hr) | ||
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| RU2470918C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β | |
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| JP2008513516A5 (hr) | ||
| HRP20140012T1 (hr) | C-met modulatori i postupci uporabe | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| UA122205C2 (uk) | Сполука циклопропанаміну та її застосування | |
| MX2009010951A (es) | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. | |
| HRP20220864T1 (hr) | Derivati n-piridinil acetamida kao inhibitori signalnog puta wnt | |
| CN105189493A (zh) | 新型吡唑衍生物 | |
| CN102746285A (zh) | 作为hedgehog途径调节剂的化合物和组合物 | |
| ATE525351T1 (de) | Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| ATE412638T1 (de) | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| CN101855227B (zh) | 杂环衍生物 | |
| SI2605652T1 (en) | Diketones and hydroxyketones as catenin signaling pathways | |
| HRP20120913T1 (hr) | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| HRP20140336T1 (hr) | Inhibitori glicin transportera-1 | |
| JP2015521642A5 (hr) | ||
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез | |
| EA200870074A1 (ru) | Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1 |